Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1993-06-01
1999-03-23
Hutzell, Paula K.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241441, 5303873, 53038822, 43524027, A61K 39395
Patent
active
058855734
ABSTRACT:
The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb. Disclosed is a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor (FcR) binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. Also disclosed is an amino acid mutation from the contiguous phenylalanine at position 234 to a leucine (Leu-234).
REFERENCES:
patent: 4658019 (1987-04-01), Kung et al.
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4830852 (1989-05-01), Marburg et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 5624821 (1997-04-01), Winter et al.
Alegre et al., "A Non-Activating Humanized Anti-CD3 Monoclonal Antibody Retains Immunosuppresive Properties In Vivo," Transplantation, 57(11):1537-1543, 1994.
Alegre et al., "Effect of a Single Amino Acid Mutation on the Activating and Immunosuppresive Properties of a Humanized OKT3 Monoclonal Antibody," The Journal of Immunology, 148(11):3461-3468, 1992.
Ortho Multicenter Transplant Study Group, "A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Gadaveric Renal Transplants," The New England Journal of Medicine, 313(6):337-342, 1985.
Thistlehwaite, Jr. et al., "OKT3 Treatment of Steroid-Resistant Renal Allograft Rejection," Transplantation, 43(2):176-184, 1997.
Chatenoud et al., "Systematic Reaction to the Anti-T-Cell Monoclonal Antibody OKT3 in Relation to Serum Levels of Tumor Necrosis Factor and Interferon-.alpha.," The New England Journal of Medicine, 320(41):1420-1421.
Parlevliet et al., "Anti-CD3 Murine Monoclonal Isotype Switch Variants Tested for Toxicity and Immunologic Monitoring in Four Chimpanzees," Transplantation, 50(5):889-892, 1990.
Alegre et al., "Cytokine Release Syndrome Induced by the 145-2C11 Anti-CD3 Monoclonal Antibody in Mice: Prevention by High Doses of Methylprednisolone," The Journal of Immunology, 146(4) :1184-1191, 1991.
Waid et al., "Treatment of Acute Cellular Rejection with T10B9.1A-31 or OKT3 in Renal Allograft Recipients," Transplantation, 53(1):80-86, 1992.
Woodle et al., "Humanized OKT3 Antibodies: Successful Transfer of Immune Modulating Properties and Idiotype Expression," The Journal of Immunology, 148(9):2756-2763, 1992.
Burton, "Immunoglobin G: Functional Sites," Monocular Immunology, 22(3):161-206, 1985.
Partridge et al., "The Use of Anti-IgG Monoclonal Antibodies in Mapping the Monocyte Receptor Site in IgG," Molecular Immunology, 23(12):1365-1372, 1986.
Duncan et al., "Localization of the binding site for the human high-affinity Fc receptor on IgG," Nature, 332:563-564, 1988.
Jefferis et al., "Molecular Definition of Interaction Sites on Human IgG for Fc Receptors (huFc.gamma.R)," Molecular Immunology, 27(12):1237-1240, 1990.
Gergely and Sarmay, "The two binding-site models of human IgG binding Fc.gamma. receptors," The FASEB Journal, 4:3275-3283, 1990.
Bolt et al., "The Generation of a Humanized, Non-mitogenic CD3 Monoclonal Antibody Which Retains in vitro Immunosuppressive Porperties," Eur. J. Immunol., 23:403-411, 1993.
Jolliffe, Linda K., "Humanized Antibodies; Enhancing Therapeutic Utility Through Antibody Engineering," Intern. Rev. Immunol., 10:241-250, 1993.
Alegre et al. J. Am. Soc. Nephrol. 2(3), 530, 1991.
Harlow et al., Antibodies a Laboratory Manual, Cold Spring Harbor Laboratory Press 1988, pp. 285, 287.
Bluestone Jeffrey A.
Jolliffe Linda K.
Zivin Robert A.
ARCH Development Corporation
Hutzell Paula K.
Ortho Pharmaceutical Corporation
LandOfFree
Methods and materials for modulation of the immunosuppressive ac does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and materials for modulation of the immunosuppressive ac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and materials for modulation of the immunosuppressive ac will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2122555